BioPlus Obtains Special Import Approval for 2 Types of Hyaluronic Acid Fillers... "Sales to Begin in Earnest"

[Asia Economy Reporter Jang Hyowon] BioPlus (CEO Jeong Hyungyu) announced on the 11th that it has obtained special import approval from the Hainan Boao Lecheng Medical Pilot Zone under the Hainan Drug Administration for two of its hyaluronic acid filler products.

The approved products are medical aesthetic hyaluronic acid skin fillers: the body filler 'DeneB' applied to the chest and buttocks, and the filler 'Skin Plus HYAL Implant' applied to the face, including the forehead, nose, and chin.

With the special import approval for these products, BioPlus plans to directly import the products and begin aesthetic procedures through its franchise hospital, which opened in February within the Ciming Boao International Hospital. Related sales are expected to begin in the third quarter.

Based on its independently developed MDM patented technology, BioPlus maximized the molding power, safety, viscoelasticity, and durability of its hyaluronic acid fillers by applying a multi-stage purification process and optimal cross-linking technology. In particular, the 'DeneB' body filler series filled the gap in the Chinese aesthetic market where no hyaluronic acid fillers were approved for breast augmentation, and it is expected to meet new medical aesthetic demands.

Following this special import approval, BioPlus plans to pursue fast-track clinical approval from the NMPA (National Medical Products Administration of China) starting next year, aiming to obtain mainland China approval by December 2023 and sell nationwide. The company also aims to open 30 aesthetic franchise hospitals in China within the next five years.

A BioPlus official stated, “China is forming a global medical market, and the aesthetic surgery sector is recording high growth annually. The company’s long-prepared China entry business is showing steady phased results, and once local sales fully commence, it will further enhance the company’s performance and competitiveness.”

Meanwhile, Ciming Boao International Hospital, located in the Hainan Boao Lecheng Medical Pilot Zone, which offers preferential policies for imported medical device approvals, clinical research, and clinical use, is a direct beneficiary hospital. It is operated by Ciming Checkup Group, a leading health screening company in China.

This content was produced with the assistance of AI translation services.